Chronic lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) can damage lung tissue, restrict breathing and reduce the body’s ability to repair itself. In IPF, scar tissue builds up around the air sacs, making it harder for oxygen to pass into the bloodstream. Treatments can slow aspects of disease progression, but repairing damaged lung tissue remains a challenge. Researchers have therefore investigated whether certain cells, or substances released by them, could reduce inflammation and fibrosis. This work has moved from laboratory experiments to early-stage clinical studies, where safety, biological effects and possible benefits must be assessed separately.
One researcher involved in this field is Yuben Moodley, a respiratory physician and academic at the University of Western Australia (UWA), who has investigated the cellular mechanisms of lung scarring and the potential use of cell-based treatments. His research has covered fibroblast signaling, stem cells derived from umbilical cord and placental tissue, and mesenchymal stromal cells in people with COPD. The work spans laboratory studies, animal models and clinical research. These stages address different questions: experiments can identify biological effects, while clinical studies must determine whether an approach is safe and whether those effects translate into meaningful outcomes for patients.
In 2003, Moodley and colleagues published a study in The American Journal of Pathology examining how lung fibroblasts from people with IPF responded to interleukin-6 (IL-6), a signaling molecule involved in inflammation and cell activity. The researchers compared fibroblasts from normal lungs with those from IPF patients. They found differences in the pathways that controlled cell growth. In normal fibroblasts, IL-6 activity was associated with sustained STAT3 signaling and reduced cell proliferation. In IPF fibroblasts, the response instead involved activation of the mitogen-activated protein kinase (MAPK) pathway and increased proliferation. The study identified differences in signaling through the IL-6 receptor component gp130, pointing to abnormal cellular responses as one feature of IPF.
This work addressed a question central to fibrosis research: why do cells that normally support tissue repair behave differently in a diseased lung? Fibroblasts help maintain connective tissue, but their activity can contribute to excessive scar formation. The 2003 findings suggested that the effects of inflammatory signals depend on the state of the cells receiving them, rather than simply on the amount of a signal present. This distinction helped frame later research into the biological processes behind lung injury and repair. It did not establish a treatment for IPF, but it offered a basis for further investigation of the pathways involved.
In 2009, Moodley and colleagues published research in The American Journal of Pathology on human umbilical cord-derived mesenchymal stem cells. Using a mouse model of bleomycin-induced lung injury, the team found that treatment with these cells reduced fibrosis. The study examined whether cells obtained from umbilical cord tissue could influence the processes that lead to scarring after lung damage. Although the findings offered a possible direction for regenerative medicine, they came from an animal model. They did not establish that the approach would work in people with chronic lung disease.
A related study followed in 2010 in the American Journal of Respiratory and Critical Care Medicine. Moodley and his co-authors examined human amnion epithelial cells, which can be isolated from the membrane surrounding a fetus during pregnancy. In mice with bleomycin-induced lung injury, the transplanted cells remained detectable in the lungs during the four-week observation period. The researchers reported lower inflammation and reduced collagen content, a major component of scar tissue. They also observed changes in proteins associated with tissue repair. The results suggested that amnion epithelial cells might affect both inflammation and fibrosis. However, further research was needed before considering their use in clinical treatment.
In 2013, Moodley and colleagues extended this work through a comparative study published in PLOS ONE. The team tested three cell types: amnion-derived mesenchymal stem cells, bone-marrow-derived mesenchymal stem cells and human amniotic epithelial cells. Unlike models based on a single injury, the experiment used repeated doses of bleomycin to represent ongoing damage better. All three cell types reduced some measures of inflammation in the mice. However, the effects were not identical. Amnion-derived mesenchymal stem cells were the only group associated with reduced collagen deposition and increased activity of matrix metalloproteinase-9, an enzyme involved in breaking down components of scar tissue. The authors concluded that this cell type warranted further investigation in settings involving repeated lung injury.
A later stage of Moodley’s work examined whether mesenchymal stromal cells could be administered safely to people with stable COPD. A Phase I pilot study published in the European Respiratory Journal in 2018 investigated cell infusion and its effects on systemic immune responses. The Australian study included nine patients and used imaging with indium-111-labelled cells to examine their distribution after infusion. The researchers detected labelled material in the lungs, followed by the liver, spleen and bone marrow. The study also recorded changes in inflammatory markers, including IL-6 and soluble CD163. Lung function did not significantly improve in the small group, underscoring the difference between observing a biological response and demonstrating clinical benefit.
Other clinical research has examined whether a patient’s inflammatory state could affect the response to mesenchymal stromal-cell treatment. A 2021 analysis by Daniel Weiss and colleagues revisited data from an earlier placebo-controlled COPD trial involving 62 patients who received four monthly infusions of remestemcel-L, a bone-marrow-derived mesenchymal stromal-cell product, or placebo. In a post-hoc analysis, patients whose baseline C-reactive protein (CRP) level was at least 4 milligrams per liter showed improvements in some measures of lung function and walking distance after treatment. These differences were not found consistently across the full patient group, and the study did not find significant benefits in reported symptoms or COPD exacerbation frequency. The findings were therefore considered a reason for further investigation, not proof of an established treatment.
Research into regenerative approaches has also expanded beyond administering whole cells. Mesenchymal stromal cells release substances that can influence immune activity, and researchers have investigated whether these cell-derived products might offer an alternative way to study or deliver their effects. Moodley’s group has examined conditioned medium, the liquid collected from cell cultures, as well as extracellular vesicles, small particles that carry biological material between cells. This approach is relevant because it may help researchers investigate which components of cell activity influence inflammation without necessarily relying on the cells themselves. However, the contents, biological effects and clinical value of these products require careful testing.
One clinical study listed in the Australian New Zealand Clinical Trials Registry examined nebulised media from mesenchymal stromal-cell cultures for moderate to severe COPD and for patients who experience frequent exacerbations. The protocol, registered as ACTRN12621001422819, set out to assess safety and potential effects on quality of life, exercise tolerance, lung function and systemic inflammatory markers. The registry now lists the study as completed. Its design reflects a shift from intravenous cell infusion towards investigating whether cell-derived substances can be delivered through inhalation.
Across this research, the central question has moved from how lung cells respond to inflammatory signals to whether cell-based approaches can alter disease processes in people. The findings include reduced fibrosis in animal models, measurable immune changes after infusion and preliminary signals in selected patient subgroups. They also show the limits of translating laboratory results into treatment. Further clinical assessment is needed to establish which patients, if any, may benefit and whether the effects are sustained. Yuben Moodley’s work in cellular and regenerative respiratory research continues to span experimental biology, clinical studies and the investigation of cell-derived products, with safety and demonstrated patient outcomes remaining key measures of progress.











































































